Cargando…

An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children's Oncology Group Study ACNS0331)

PURPOSE: Craniospinal irradiation remains an essential and yet difficult part of the treatment of patients with medulloblastoma. Whereas technological advances offer promise of increased conformity, realiance on advanced technology is not without risk, and it remains critical to carefully delineate...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiff, Joshua P., Lee, Yimei, Wang, Yu, Perkins, Stephanie M., Kessel, Sandy K., Fitzgerald, Thomas J., Larrier, Nicole A., Michalski, Jeff M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723303/
https://www.ncbi.nlm.nih.gov/pubmed/36483060
http://dx.doi.org/10.1016/j.adro.2022.101083
_version_ 1784844141382860800
author Schiff, Joshua P.
Lee, Yimei
Wang, Yu
Perkins, Stephanie M.
Kessel, Sandy K.
Fitzgerald, Thomas J.
Larrier, Nicole A.
Michalski, Jeff M.
author_facet Schiff, Joshua P.
Lee, Yimei
Wang, Yu
Perkins, Stephanie M.
Kessel, Sandy K.
Fitzgerald, Thomas J.
Larrier, Nicole A.
Michalski, Jeff M.
author_sort Schiff, Joshua P.
collection PubMed
description PURPOSE: Craniospinal irradiation remains an essential and yet difficult part of the treatment of patients with medulloblastoma. Whereas technological advances offer promise of increased conformity, realiance on advanced technology is not without risk, and it remains critical to carefully delineate targets. We describe examples of target deviations (TDs) in craniospinal irradiation treatment plans for postoperative patients with medulloblastoma in a phase 3 clinical trial (ACNS 0331). METHODS AND MATERIALS: The principal investigator independently performed a review of the treatment plans and portal films of enrolled patients and evaluated the plans for TDs. TDs of dose, dose uniformity, and volume were defined as major or minor deviations. Major TDs scored as protocol violations. The effect of major TDs on event-free survival (EFS) and overall survival (OS) was evaluated using the stratified Cox proportional hazards model. RESULTS: Of the 549 patients enrolled, 461 were available for this analysis. Thirty-two (7%) plans did not have data sufficient for TD evaluation. Major TDs were found in 32 of the 461 plans (7%). Of those, 21 were deviations of target volume alone, 7 were deviations of target dose alone, and 4 were deviations of both target volume and dose. The 25 patients with TDs of volume involved 29 sites. The most common major TDs of volume involved the brain (9 of 29) and the posterior fossa (9 of 29). On Cox proportional hazards modeling, the presence of a major TD did not statistically significantly affect EFS (hazard ratio, 0.98; 95% confidence interval, 0.45-2.11; P = .9541) or OS (hazard ratio, 1.10; 95% confidence interval, 0.51-2.38; P = .8113). CONCLUSIONS: Although intensity modulated radiation therapy and proton therapy are promising in improving conformity and sparing organs at risk, technology does not substitute for careful anatomic definition of target volumes. The study was not powered to evaluate the effect of TDs on EFS and OS; therefore, the statistical analysis presented in this study must be interpreted with caution.
format Online
Article
Text
id pubmed-9723303
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97233032022-12-07 An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children's Oncology Group Study ACNS0331) Schiff, Joshua P. Lee, Yimei Wang, Yu Perkins, Stephanie M. Kessel, Sandy K. Fitzgerald, Thomas J. Larrier, Nicole A. Michalski, Jeff M. Adv Radiat Oncol Research Letter PURPOSE: Craniospinal irradiation remains an essential and yet difficult part of the treatment of patients with medulloblastoma. Whereas technological advances offer promise of increased conformity, realiance on advanced technology is not without risk, and it remains critical to carefully delineate targets. We describe examples of target deviations (TDs) in craniospinal irradiation treatment plans for postoperative patients with medulloblastoma in a phase 3 clinical trial (ACNS 0331). METHODS AND MATERIALS: The principal investigator independently performed a review of the treatment plans and portal films of enrolled patients and evaluated the plans for TDs. TDs of dose, dose uniformity, and volume were defined as major or minor deviations. Major TDs scored as protocol violations. The effect of major TDs on event-free survival (EFS) and overall survival (OS) was evaluated using the stratified Cox proportional hazards model. RESULTS: Of the 549 patients enrolled, 461 were available for this analysis. Thirty-two (7%) plans did not have data sufficient for TD evaluation. Major TDs were found in 32 of the 461 plans (7%). Of those, 21 were deviations of target volume alone, 7 were deviations of target dose alone, and 4 were deviations of both target volume and dose. The 25 patients with TDs of volume involved 29 sites. The most common major TDs of volume involved the brain (9 of 29) and the posterior fossa (9 of 29). On Cox proportional hazards modeling, the presence of a major TD did not statistically significantly affect EFS (hazard ratio, 0.98; 95% confidence interval, 0.45-2.11; P = .9541) or OS (hazard ratio, 1.10; 95% confidence interval, 0.51-2.38; P = .8113). CONCLUSIONS: Although intensity modulated radiation therapy and proton therapy are promising in improving conformity and sparing organs at risk, technology does not substitute for careful anatomic definition of target volumes. The study was not powered to evaluate the effect of TDs on EFS and OS; therefore, the statistical analysis presented in this study must be interpreted with caution. Elsevier 2022-09-24 /pmc/articles/PMC9723303/ /pubmed/36483060 http://dx.doi.org/10.1016/j.adro.2022.101083 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Letter
Schiff, Joshua P.
Lee, Yimei
Wang, Yu
Perkins, Stephanie M.
Kessel, Sandy K.
Fitzgerald, Thomas J.
Larrier, Nicole A.
Michalski, Jeff M.
An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children's Oncology Group Study ACNS0331)
title An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children's Oncology Group Study ACNS0331)
title_full An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children's Oncology Group Study ACNS0331)
title_fullStr An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children's Oncology Group Study ACNS0331)
title_full_unstemmed An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children's Oncology Group Study ACNS0331)
title_short An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children's Oncology Group Study ACNS0331)
title_sort analysis of major target deviations in craniospinal irradiation treatment plans for patients with intermediate-risk medulloblastoma within a phase 3 clinical trial (children's oncology group study acns0331)
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723303/
https://www.ncbi.nlm.nih.gov/pubmed/36483060
http://dx.doi.org/10.1016/j.adro.2022.101083
work_keys_str_mv AT schiffjoshuap ananalysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT leeyimei ananalysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT wangyu ananalysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT perkinsstephaniem ananalysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT kesselsandyk ananalysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT fitzgeraldthomasj ananalysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT larriernicolea ananalysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT michalskijeffm ananalysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT schiffjoshuap analysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT leeyimei analysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT wangyu analysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT perkinsstephaniem analysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT kesselsandyk analysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT fitzgeraldthomasj analysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT larriernicolea analysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331
AT michalskijeffm analysisofmajortargetdeviationsincraniospinalirradiationtreatmentplansforpatientswithintermediateriskmedulloblastomawithinaphase3clinicaltrialchildrensoncologygroupstudyacns0331